Dr. Kumar on Utility of ASCT in Newly Diagnosed Multiple Myeloma

Video

Shaji Kumar, MD, of Mayo Clinic, advises physicians on the use of autologous stem cell transplant in patients with newly diagnosed multiple myeloma.

Shaji Kumar, MD, a consultant in hematology at the Mayo Clinic, advises physicians on the use of autologous stem cell transplantation (ASCT) in patients with newly diagnosed multiple myeloma.

Kumar says his key message is that, for patients with newly diagnosed disease, they should always be considered for ASCT. Additionally, in scenarios with an older patient with multiple myeloma who is in good physical health and no significant comorbidities, ASCT should be discussed and considered.

Even if a physician is in doubt of whether a patient is a good candidate for ASCT, the patient should always be referred to a transplant center where they can be assessed and the procedure can be discussed in greater detail. This will allow a patient to make an informed decision on their treatment, Kumar says.

<<< 2019 Transplantation and Cellular Therapy Meetings

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
James Knight, MD
Vlad Gabriel Zaha, MD, PhD